Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could two weeks of heart monitoring prevent a second stroke?

NCT ID NCT05134454

Disease control Sponsor: Karolinska Institutet Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This study asks whether wearing a small heart monitor for two weeks at a time, twice, can better detect hidden irregular heartbeats (atrial fibrillation) in older adults who recently had a stroke or mini-stroke, compared to the usual 1-2 day monitoring. Atrial fibrillation is a major risk factor for stroke, and finding it could lead to blood thinners that lower the chance of another stroke. The trial enrolls 3,300 patients aged 70 and older and tracks their health over time to see if extended monitoring reduces strokes, deaths, or serious bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Extended ECG monitoring using a wearable patch (Philips ePatch) worn for 14 days, repeated twice, compared to standard 1-2 day ECG monitoring.
What this could lead to
If extended monitoring detects more atrial fibrillation, it could enable earlier anticoagulation treatment, potentially reducing recurrent strokes and deaths in elderly stroke survivors.
What could go wrong
The trial is large but still experimental; extended monitoring may not significantly improve outcomes, and the added detection could lead to unnecessary treatments or bleeding risks from anticoagulants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3,300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2022

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

70 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged ≥ 70 years * A diagnosis of ischemic stroke or TIA within 14 days from inclusion. Exclusion Criteria: * Previously diagnosed atrial fibrillation * Contraindication to oral anticoagulant treatment according to Summary of Product Characteristics. * Indication for anticoagulant treatment other than atrial fibrillation, e.g. venous thromboembolism or mechanical heart valve prosthesis * Dual antiplatelet therapy not interchangeable to oral anticoagulation * Patients with pacemaker, implantable cardioverter defibrillator or implantable cardiac monitor. * Patients who, according to the investigator, will not be able to comply with the study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation ischemic stroke stroke disorder transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic stroke TIA

Contacts and locations

Locations

  • Karolinska Institutet Danderyds University Hospital

    Stockholm, Stockholm County, 18288, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.